Company: TBPH
Filing Date: 2025-06-02
Form Type: 8-K
Source: 0001104659-25-055100
Chunk: 2

Company: Theravance Biopharma, Inc.
Filing Date: 2025-06-02
Form: 8-K
Item: Item 7.01
Chunk 2
---
Item
7.01. Regulation FD Disclosure

.

On June 2, 2025, TBPH issued a press release relating to the Assignment
Agreement. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

The disclosure set forth in Item 7.01 of this Current Report on Form
8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The disclosure set forth in Item 7.01 of this
Current Report on Form 8-K (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

   2.1      Assignment Agreement, dated May 30, 2025, by and between Theravance Biopharma, Inc. and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered...  
  99.1      Press Release dated June 2, 2025                                                                                                                                                                      
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
   104      Cover Page Interactive Data File (cover page XBRL tags embedded within the Inline XBRL document)                                                                                                      

SIGNATURE

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                          THERAVANCE BIOPHARMA, INC.                                                         
  Date: June 2, 2025      By:                             /s/ Aziz Sawaf                                     
                                                          Aziz Sawaf                                         
                                                          Senior Vice President and Chief Financial Officer